Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
12
×
venture capital
12
×
boston blog main
life sciences
national blog main
boston top stories
national top stories
startups
clinical trials
san francisco blog main
san francisco top stories
boston
cancer
fda
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
financing
indiana blog main
indiana top stories
investing
national
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
biogen
deals
What
new
bio
medicines
roundup
ipo
ceo
covid
drug
drugs
founders
health
help
hit
investors
market
medicine
neuro
patients
proteins
raised
research
abbvie’s
acquisitions
active
activity
advance
advantages
advice
aiming
aims
analytics
analyze
anemia
announced
approach
approvals
asked
associated
backed
background
Language
unset
12
×
Current search:
biotech
×
" venture capital "
×
unset
×
@techcrunch.com
2 years ago
8 cannabis investors share their outlook on the European market in H1 2022
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@techcrunch.com
4 years ago
What tech gets right about healthcare